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Abstract
Background: Precision medicine may offer new strategies to treat migraine, and access to existing large cohorts
may be a key resource to increase statistical power. Treatment response data is not routinely collected for large
cohorts; however, such information could be extracted from pharmacy databases. Using a clinical migraine sample
with treatment effect data, we assessed whether treatment response can be predicted based on the number of
drug purchases.
Methods: A clinical cohort including 1913 migraineurs were interviewed using a semi-structured interview to
retrieve treatment response data for acute and prophylactic migraine drugs. The purchase history was obtained
from the Danish national pharmacy database. We assessed whether number of purchases at different thresholds
could predict the specificity and sensitivity of treatment response.
Results: Purchase history of drugs was significantly associated with treatment response. For triptan treatment the
specificity and sensitivity were above 80% for individuals with at least ten purchases. For prophylactic treatment
(beta-blockers, angiotensin II antagonists or antiepileptic) we observed a sensitivity and specificity above 80% and
50% for individuals purchasing any prophylactic drug at least four times. In the Danish pharmacy database, 73% of
the migraine patients have purchased at least ten triptans, while 55–63% have purchased at least one of the four
prophylactic drugs.
Conclusion: Pharmacy databases are a valid source for identification of treatment response. Specifically for
migraine drugs, we conclude that ten purchases of triptans or four purchases of prophylactic drugs are sufficient to
predict a positive treatment response. Precision medicine may be accelerated with the use of pharmacy databases.
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Background
The success of precision medicine depends on the ability
to identify patient groups with a specific response to a
drug. The predictive power to classify patients depends
on the quality and size of the initial cohort used to build
the models [1]. Retrieving treatment response data for a
large cohort is resource intensive and can take a long
time. Identification of treatment response markers, e.g.
in existing pharmacological databases that are easily
accessible, is an alternative and simple strategy for asses-
sing large cohorts. Although several countries maintain
registry databases with information on individual medi-
cation use [2], this approach has never been tested. Mi-
graine is an ideal condition to test the accuracy of
prediction of treatment response from pharmacological
databases. Migraine affects 15–20% of the population [3]
and both acute and prophylactic treatments are available
[4]. Triptans are migraine-specific acute drugs with no
effect on peripheral pain [5] and are reported to be ef-
fective in 60–70% of treated migraine patients [6]. There
are several (non-specific) prophylactic drugs for mi-
graine available and the current choice of prophylactic
treatment is made by trial and error [4, 7].
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In Denmark, the national pharmacy database holds
individual-level data on all prescriptions and subsequent
purchases of drugs [8]. In a large clinical sample of mi-
graine patients, we have collected information regarding
migraine treatment response for both acute and prophy-
lactic drugs [9]. We hypothesized that drug purchases
can predict treatment response. To test this hypothesis,
we combined the Danish pharmacy database with our
clinical migraine sample and provide an estimate of the
sensitivity and specificity to predict treatment response.
Methods
Patients were recruited as part of the migraine genetic
cohort at the Danish Headache Centre (tertiary head-
ache referral centre) from 2010 to 2016. All patients
were interviewed by medical doctors or senior medical
students specifically trained in using a semi-structured
interview to diagnose headache according to the Inter-
national Classification of Headache Disorders (ICHD)
[10]. A total of 1913 migraine patients with or without
typical aura answered questions regarding medication use
and treatment response to relevant headache pharmaco-
logical treatments including acute treatment (following
categories: triptans (general, non-specific), ergotamine,
non-migraine specific analgesics) and prophylactic treat-
ment (following categories: Beta-blockers, Angiotensin II
antagonists, Antiepileptics, ACE-inhibitors, and Anti-de-
pressives). Acute treatment effect was considered positive
if the patient reported at least 50% pain reduction within
two hours of taking the drug. Prophylactic treatment was
considered effective if the patient reported a reduction of
at least 50% in the number of migraine attacks with three
months of drug use. Patients who did not remember or
had not tried the medication in question were registered
as missing data.
The Danish medical prescription register is a national
database in which all purchases of drugs prescribed by a
medical doctor have been registered since 1994; data
from 1994 until 2016 was included in the analysis. The
register is primarily used for socioeconomic evaluation
of medication use in Denmark. Prescription data for
headache treatments often used in Denmark (Table 1)
were merged at Denmark Statistics where study par-
ticipants were fully anonymized. In Denmark, it is
possible to buy non-migraine specific analgesics over
the counter (OTC) and it is not possible to retrieve
information about the purchase of non-migraine
specific analgesics.
Statistics
We used R version 3.4.1 in RStudio version 2.1 for statis-
tical analysis, with the R packages sas7bdat, ggplot2, caret,
and ROCR. We created a confusion matrix for treatments
reported with the effective measure in more than 5% (n =
100) of the assessed patients and used the confusion
matrix function from the R package (caret to retrieve spe-
cificity, sensitivity and accuracy [11]. To test the influence
of age, gender, and the interaction thereof, we used
logistic regression to compare the contribution of
each covariate towards the treatment effect and the
influence on receiver operating characteristics (ROC).
The number of purchases is given as median and
quartiles as these data are not normally distributed.
Results
A total of 1913 migraine patients were questioned about
the use and effect of acute and prophylactic migraine
Table 1 Drugs assessed in pharmacy database
Drug ATC Code
Acute Triptans
Sumatriptan N02CC01
Zolmitriptan N02CC03
Naratriptan N02CC02
Rizatriptan N02CC04
Almotriptan N02CC05
Eletriptan N02CC06
Frovatriptan N02CC07
Ergot alkaloids
Ergotamine N02CA52
Non-migraine specific analgesics
Paracetamol N02BE01
Treo N02BA51
Ibuprofen M01AE01
Naproxen M01AE02
Tolfenamsyre M01AG02
Diclofenac M01AB05
Prophylactic Beta-blocker
Metoprolol C07AB02
Propranolol C07AA05
Angiotensin II antagonist
Candesartancilexetil C09CA06
ACE Inhibitor
Lisinopril C09AA03
Antiepileptics
Topiramate N03AX11
Valproate N03AG01
Antidepressive
Amitriptyline N06AA09
Others
Pizotifen N02CX01
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treatments. Treatment effect of ACE-inhibitors and
anti-depressive medication were reported by less than
5% and were only included in the combined analysis of
all prophylactic treatments, see Table 2.
Acute treatment
Increased number of purchases was significantly associ-
ated with a reporting of positive effect of any acute treat-
ment (p < 1e-16). However, this signal was markedly
driven by triptan purchase (Fig. 1), as both ergotamine
and non-migraine specific analgesics did not differ
regarding treatment effect (p > 0.05). Distribution of er-
gotamine and non-migraine specific analgesic acute
treatments is presented in Additional file 1: Figure S1.
Using logistic regression, we included age and gender
but did not find a significant contribution to the ROC-
curve, see Additional file 1: Figure S5. We calculated the
sensitivity, specificity and accuracy at different thresh-
olds for the number of purchases of triptans for predic-
tion of a positive treatment response using a simple
confusion matrix (Fig. 2). The overall sensitivity, i.e. the
ability to identify a true positive response (Fig. 2 - green
line), was above 80% at all triptan purchase thresholds
analysed. However, the specificity, i.e. the ability to
detect a true negative response, depended more on the
number of purchases. Here, at least ten purchases were
needed to gain 70% specificity (Fig. 2 - blue line). Here,
73% of the cohort purchased at least ten triptans (Fig. 1).
The accuracy, i.e. the ability to predict overall true find-
ings, was above 80% at all thresholds of purchases ana-
lysed. As triptans are known to have higher efficacy in
migraine without aura than in migraine with aura, we
repeated the analysis excluding migraine with aura pa-
tients [12]. Although reducing the statistical power, we
found a generally better sensitivity but a lower specificity
for migraine without aura, see Additional file 1: Figure S3.
In Denmark, it is clinical practice for neurologists to
try at least three different triptans before concluding that
triptans do not have an effect (personal communication
prof. Jes Olesen). Thus, we tested whether having tried
four or more different triptans could indicate a negative
treatment response. We calculated a sensitivity of 21%
and a specificity of 73% to predict a negative treatment
response with an accuracy of 63%, see the distribution in
Additional file 1: Figure S2. Furthermore, using the
number of purchases we tested whether having only one
prescription could predict negative treatment re-
sponse. We found a sensitivity of 80% and a specifi-
city of 6% with an accuracy of 20%. For the most
prescribed drug, sumatriptan, we also analysed whether
patients in monotherapy (n = 50) had different purchase
number with a sensitivity of 80%. Noting that the number
of patients in monotherapy was small, we observed that
fewer, six purchases, gave the same results as for all
triptans combined.
Prophylactic treatment
We identified an association between the number of
purchases of prophylactic drug and a positive treatment
effect (p < 1e16), see Fig. 3. The results did not change
when excluding patients with comorbid epilepsy (n = 85)
or hypertension (n = 473), although the average number
of purchases dropped significantly for antiepileptics, see
Additional file 1: Figure S4. To obtain a specificity above
50%, at least three purchases of angiotensin II antagonist
and antiepileptics and four purchases for beta-blockers
was needed (Fig. 4 - blue line). We observed that 68, 63,
and 63% of the sample had purchased angiotensin II an-
tagonist and antiepileptic three times and beta-blockers
four times. The sensitivity is relatively high (> 80%) for
four purchases or less.
Discussion
Using a large clinical migraine cohort (n = 1913) includ-
ing information on treatment response, we found a
highly significant association between the number of
Table 2 Number of patients with or without an effect of migraine medication
Treatment
All (n = 1913) Males (n = 540) Females (n = 1373)
Drug category Yes No Yes No Yes No
Acute Triptans 1113 252 252 65 861 187
Non-migraine specific analgesics 482 1080 159 288 323 792
Ergotamine 89 132 23 21 66 111
Prophylactic Beta-blocker 187 486 33 112 154 374
Angiotensin II antagonists 232 325 47 73 185 252
Antiepileptic 120 325 28 69 92 256
ACE-inhibitor a 1 21 1 14 – 7
Anti-depressive a 3 27 3 17 – 10
aNot analyzed individually
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purchases of triptans and positive treatment response,
defined as having at least 50% reduction in symptoms
within two hours of treatment start. We showed that the
sensitivity was high (> 80%) for prediction of positive
response to triptans and that the sensitivity was above
70% if the patients had more than ten purchases. We
did not find evidence for an association between treat-
ment response and purchases of non-migraine specific
Fig. 1 Distribution of triptan purchases. The figure depicts the distribution of triptan purchases, a) as a boxplot of individuals reporting a
treatment effect of triptans (YES), no effect (NO) and b) as stacked histograms showing the distribution of triptan effect among patients with a
minimum number of purchases of triptans on the x-axis and the total number of patients above each bar. Since the Danish legislation does not
allow depicting individual data, outliers are excluded in a
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analgesics or ergotamines. We did not expect to observe
an association, as non-migraine specific analgesics can
be bought over-the-counter and are used for many
other indications putatively introducing substantial
statistical noise.
It is expected that migraine patients who purchase
triptans more than once only do so if they experience a
positive response. However, we observed an expected
increase in sensitivity with number of purchases, al-
though ten purchases of triptans were needed to reach
70% sensitivity. Since this is a retrospective study, this
may be a consequence of recall bias. In addition, the
positive response criterion of having 50% reduction of
symptoms within two hours might exclude patients
with marginally less or slower effect of triptans. An in-
teresting future study would be to assess the individual
migraine drugs. We demonstrated that analysing single
drugs necessitates fewer purchases of the drug to gain
the 80% specificity. However, a larger sample size is
needed and, although more labour intensive, prospect-
ive studies may be needed. However, a key future goal
is to compare treatment outcome with genetics, which
requires that all participants must be genotyped. Here,
thousands of patients are usually required to gain
enough statistical power to assess common variants.
Thus, a prospective migraine diary-based study seems
less feasible.
We found a highly significant association between pur-
chases of prophylactic drugs and a positive treatment re-
sponse, defined as a more than a 50% reduction of their
migraine attacks, from using angiotensin II antagonists,
beta-blockers, or antiepileptics. We found a high sensitiv-
ity (> 80%) predicting positive treatment response from
the number of purchases, and a specificity above 70% after
at least three or four purchases depending on the drug.
Whereas triptans are specific migraine drugs, the prophy-
lactic drugs are not. As a result, the prediction model for
prophylactic drugs necessitates knowledge of the prescrip-
tion indication. Some drugs may be used to treat a multi-
tude of conditions (e.g. epilepsy, arterial hypertension).
Hence, we repeated the analysis excluding patients with
comorbid disease. The association remained significant,
Fig. 2 The sensitivity and specificity for triptan purchases to predict a positive treatment response. The figure presents the sensitivity (green) and
specificity (blue) at different thresholds of minimum number of triptan-purchases, e.g. patients with ten or more triptan purchases had a
sensitivity of 82% and specificity of 66% for prediction of positive treatment response (red line)
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although we observed a significant drop in the average
number of purchases of antiepileptics.
Our study design included general triptan use and
response, thus we were unable to test for an associ-
ation between number of different triptans purchased
and patients reporting no treatment effect. Future
studies including more complex analysis of the types
of triptans, patterns of medication exposures, etc.,
may aid in the characterization of migraine patient
groups.
Precision medicine may offer new strategies to treat
migraine, and access to existing large cohorts and
pharmacy databases may help reach the required lar-
ger sample sizes. Based on the current results we rec-
ommend using ten purchases for triptans and three
or four purchases for prophylactics. We anticipate
that using fewer purchases, e.g. three triptans, may be
sufficient; however, this should be evaluated in future
studies. Notably, more than 75% of the triptan users
have purchased triptans at least ten times, and 55–
63% of the prophylactic users have at least three or
four purchases. Additional factors may also influence
treatment response, such as the use of other drugs
[13–15], i.e. polypharmacy, as well as presence of
co-morbid disorders. Here, it is possible that temporal
aspect when additional drugs are prescribed, as a pre-
scription could reflect treatment of adverse-effects.
Further, it is easy to imagine that migraine patients
with co-morbid depression may experience a better
response to anti-depressants [16]. Most likely, genetic
factors may also condition the treatment response, as
seen for lithium and anti-psychotics [17–19], although
studies on migraine drugs so far have been inconclu-
sive or lack replication [13, 15].
Conclusions
We conclude that a national pharmacy database is a
valuable resource to identify a positive treatment re-
sponse for migraineurs. As a general recommenda-
tion, we suggest using ten purchases for triptans and
Fig. 3 Distribution of purchases of prophylactic treatment. The figure depicts the distribution of a) Angiotensin II antagonist, b) Antiepileptic, and
c) Beta-blockers prescription as a boxplot of patients reporting a treatment effect of triptans (Yes), or no effect (No). Given the Danish legislation
it is not allowed to depict individual data, thus outliers are excluded
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three or four purchases for prophylactic drugs, to
predict positive treatment response. In future studies,
more detailed information about treatment response
and failure would improve the correlation with the
number of purchases and perhaps enable us to
predict treatment failure. We expect that a lower
number of purchases than the ten suggested here
may be sufficient.
Additional file
Additional file 1: Figure S1. Distribution of prescription drugs for total
acute treatment, Ergotamine and weak analgesic. Figure S2. Distribution
of purchases given the number of different triptans purchased. Figure
S3. Distribution and prediction for purchases for migraine patients
without aura only. Figure S4. Distribution of prophylactic drugs with and
without comorbid disoders. Figure S5. Receiver operating characteristic
curve for model with and without gender and age as covariates.
Table S1. Questions from semi structured interview. (DOCX 110 kb)
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